Antimicrobial Therapies Linked to Neonatal Infection Outbreaks

Primary tabs

Antimicrobial Therapies Linked to Neonatal Infection Outbreaks

tweet me:
Antimicrobial Therapies linked to Neonatal Infection Outbreaks http://3bl.me/sfg7nb @Elsevier #health
Tuesday, October 1, 2013 - 10:45am

CONTENT: Press Release

Antimicrobial Therapies Linked to Neonatal Infection Outbreaks
 

Washington, DC, October 1, 2013 – Administration of antibiotics may have caused successive outbreaks of vancomycin-resistant enterococci (VRE) in a Greek neonatal intensive care unit (NICU), according to a study in the October issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

A team of physicians at the Aristotle University School of Medicine in Greece responded to two occurrences of VRE in their 44-bed NICU with a bundled intervention of active surveillance, enhanced infection control measures, optimization of antimicrobial usage, and investigation of potential risk factors for VRE colonization over a six-month period. Out of 253 newborns screened, 39.9 percent were found to be carriers of VRE. During the first wave of this outbreak a single clone predominated.

Antimicrobial usage, particularly administration of vancomycin and other glycopeptide antibiotics, was reduced significantly until the outbreak appeared to be over. Just as antimicrobial usage returned to previous levels, a new case of VRE was discovered and a second wave of the outbreak began.

Analysis of the data revealed antimicrobial treatment for late-onset neonatal sepsis and hospitalization during the outbreak as significant risk factors for VRE.

The authors conclude, “Both a high prevalence of VRE colonization and antimicrobial use promoted the transmission of VRE during this biphasic outbreak. Adherence to infection control measures and antimicrobial stewardship policies are of utmost importance.”

Enterococci can cause serious healthcare-associated infections in adults, children, and neonates. Vancomycin-resistant enterococci are resistant to vancomycin, the drug often used to treat serious infections for which other medicines may not work. Each year an estimated 20,000 hospitalized U.S. patients become infected with VRE, leading to approximately 1,300 deaths, according to a recent report (www.cdc.gov/drugresistance/threat-report-2013) on antibiotic resistance issued by the Centers for Disease Control and Prevention (CDC).

According to the CDC, the most important action needed to slow the spread of antibiotic-resistant infections is to improve the use of antibiotics. The CDC warns that using antibiotics when they are not needed can lead to the development of antibiotic resistance and can increase a patient’s risk of developing a resistant infection in the future.

 

# # #

 

Notes for editors
“Vancomycin-resistant Enterococcus outbreak in a neonatal intensive care unit: Epidemiology, molecular analysis, and risk factors,” by Elias Iosifidis, Ioanna Evdoridou, Eleni Agakidou, Elpis Chochliourou, Efthimia Protonotariou, Konstantina Karakoula, Ioannis Stathis, Danai Sofianou, Vassiliki Drossou-Agakidou, Spyros Pournaras, and Emmanuel Roilides appears in a special issue on pediatrics of the American Journal of Infection Control, Volume 41, Issue 10 (October 2013).

Authors

Elias Iosifidis, MD
Third Department of Pediatrics, Aristotle University School of Medicine, Hippokration General Hospital, Thessaloniki, Greece

Ioanna Evdoridou, MD, PhD
First Department of Neonatology and Neonatal Intensive Care Unit, Aristotle University School of Medicine, Hippokration General Hospital, Thessaloniki, Greece

Eleni Agakidou, MD
First Department of Neonatology and Neonatal Intensive Care Unit, Aristotle University School of Medicine, Hippokration General Hospital, Thessaloniki, Greece

Elpis Chochliourou, MD, PhD
First Department of Neonatology and Neonatal Intensive Care Unit, Aristotle University School of Medicine, Hippokration General Hospital, Thessaloniki, Greece

Efthimia Protonotariou, MD, PhD
Department of Microbiology, Aristotle Hippokration General Hospital, Thessaloniki, Greece

Konstantina Karakoula, MD
Department of Microbiology, Aristotle Hippokration General Hospital, Thessaloniki, Greece

Ioannis Stathis, RN, MSc
Infection Control Team, Hippokration General Hospital, Thessaloniki, Greece

Danai Sofianou, MD, PhD
Department of Microbiology, Aristotle Hippokration General Hospital, Thessaloniki, Greece

Vassiliki Drossou-Agakidou, MD, PhD
First Department of Neonatology and Neonatal Intensive Care Unit, Aristotle University School of Medicine, Hippokration General Hospital, Thessaloniki, Greece

Spyros Pournaras, MD, PhD
Department of Microbiology, University of Thessaly School of Medicine, Larissa, Greece

Emmanuel Roilides, MD, PhD, FIDSA (Corresponding Author)
Third Department of Pediatrics, Aristotle University School of Medicine, Hippokration General Hospital, Thessaloniki, Greece

About AJIC: American Journal Of Infection Control
AJIC: American Journal of Infection Control (www.ajicjournal.org) covers key topics and issues in infection control and epidemiology. Infection preventionists, including physicians, nurses, and epidemiologists, rely on AJIC for peer-reviewed articles covering clinical topics as well as original research. As the official publication of APIC, AJIC is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention. AJIC also publishes infection control guidelines from APIC and the CDC. Published by Elsevier, AJIC is included in MEDLINE and CINAHL.

About APIC
APIC’s mission is to create a safer world through prevention of infection. The association’s 15,000 members direct infection prevention programs that save lives and improve the bottom line for hospitals and other healthcare facilities. APIC advances its mission through patient safety, implementation science, competencies and certification, advocacy, and data standardization. Visit APIC online at www.apic.org. Follow APIC on Twitter: http://twitter.com/apic and Facebook: www.facebook.com/InfectionPreventionandYou. For information on what patients and families can do visit APIC’s Infection Prevention and You website at www.apic.org/infectionpreventionandyou.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact
Liz Garman
+1 202 454 2604
egarman@apic.org

Keywords: Pharma News, Research & Solutions | Research & Policy | antimicrobial therapy | cdc | neonatal infection | outbreak

CONTENT: Press Release

parse.ly